Olpasiran · OCEAN(a)-Outcomes
The sponsor continues the Phase 3 cardiovascular outcomes program. Lp(a)-lowering biomarker results are not proof of benefit on its coronary event endpoint. olpasiran — phase 3 study in Atherosclerotic Cardiovascular Disease. NCT05581303 measures Time to CHD death, myocardial infarction, or urgent coronary revascularization, whichever occurs first (Approximately 5 years). Registry status: active not recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
Primary evidence
Cardiovascular outcomes monitor — date unconfirmed
Potential outcome market
Will olpasiran meet the prespecified primary endpoint in NCT05581303 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.